(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia...
Stats | |
---|---|
本日の出来高 | 25.13M |
平均出来高 | 9.60M |
時価総額 | 10.23B |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0.0600 ( 2020-06-29 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 18.13 |
ATR14 | HKD0.00900 (0.33%) |
ボリューム 相関
Luye Pharma Group Ltd 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Luye Pharma Group Ltd 相関 - 通貨/商品
Luye Pharma Group Ltd 財務諸表
Annual | 2023 |
収益: | HKD6.14B |
総利益: | HKD4.20B (68.44 %) |
EPS: | HKD0.140 |
FY | 2023 |
収益: | HKD6.14B |
総利益: | HKD4.20B (68.44 %) |
EPS: | HKD0.140 |
FY | 2022 |
収益: | HKD5.98B |
総利益: | HKD4.14B (69.22 %) |
EPS: | HKD0.170 |
FY | 2021 |
収益: | HKD5.20B |
総利益: | HKD3.40B (65.32 %) |
EPS: | HKD-0.0422 |
Financial Reports:
No articles found.
Luye Pharma Group Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0370 | 2016-10-04 |
Last Dividend | HKD0.0600 | 2020-06-29 |
Next Dividend | HKD0 | N/A |
Payout Date | 2020-07-24 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.406 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.99 | -- |
Div. Sustainability Score | 8.62 | |
Div.Growth Potential Score | 4.10 | |
Div. Directional Score | 6.36 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2601.HK | Ex Dividend Knight | 2023-05-30 | Annually | 0 | 0.00% | |
1397.HK | Ex Dividend Junior | 2023-06-21 | Sporadic | 0 | 0.00% | |
0460.HK | Ex Dividend Junior | 2023-06-06 | Annually | 0 | 0.00% | |
6830.HK | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
1948.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
0978.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
0097.HK | Ex Dividend Junior | 2023-06-07 | Semi-Annually | 0 | 0.00% | |
3320.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
1538.HK | Ex Dividend Junior | 2023-06-05 | Sporadic | 0 | 0.00% | |
0586.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0867 | 1.500 | 8.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0209 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0446 | 1.500 | -0.615 | -0.923 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.315 | 0.800 | 8.42 | 6.74 | [1 - 3] |
quickRatioTTM | 0.844 | 0.800 | 9.74 | 7.79 | [0.8 - 2.5] |
cashRatioTTM | 0.398 | 1.500 | 8.90 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.330 | -1.500 | 4.50 | -6.76 | [0 - 0.6] |
interestCoverageTTM | 2.56 | 1.000 | -0.164 | -0.164 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.183 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0387 | 2.00 | 9.98 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.671 | -1.500 | 7.32 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.684 | 1.000 | 1.927 | 1.927 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.144 | 1.000 | 9.11 | 9.11 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0821 | 1.000 | -0.655 | -0.655 | [0.2 - 2] |
assetTurnoverTTM | 0.241 | 0.800 | -1.727 | -1.381 | [0.5 - 2] |
Total Score | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.77 | 1.000 | 8.31 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0446 | 2.50 | -0.395 | -0.923 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0387 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.183 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.601 | 1.500 | 2.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.112 | 1.000 | 9.69 | 0 | [0.1 - 0.5] |
Total Score | 4.10 |
Luye Pharma Group Ltd
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。